PALO ALTO, Calif., March 16, 2020 /PRNewswire/ -- Varian (NYSE: VAR) today announced its Halcyon™ 2.0 treatment system has been approved by the China National Medical Products Administration (NMPA), which allows the company to market this cancer treatment system in China. This system incorporates new imaging technologies,

SAN FRANCISCO, March 16, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) Company developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients, today reported fourth quarter and full year financial results for the period ending

NASDAQ: CORV   TSX: CORVAcquisition Expected to Have a Total Purchase Price of Approximately US$76 Million Including the Repayment of Certain Correvio IndebtednessADVANZ PHARMA Intends to Pay for the Acquisition with Cash on HandProvides ADVANZ PHARMA with an Immediate and Direct Com

Transaction in connection with the previously announced transition plan NYSE | TSX : ACB  EDMONTON, March 16, 2020 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, today announced that Ter

Provides ADVANZ PHARMA with an immediate and direct commercial presence in Germany, France, Spain, Italy, and the Benelux region, while strengthening its existing presence in the Nordics and the United Kingdom Further diversifies ADVANZ PHARMA's

ROCKVILLE, Md. and BEIJING, March 16, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2019, and

SOUTH SAN FRANCISCO, Calif., March 16, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today reported its financial results for the year ended

In the news release, ADVISORY: Online Media Briefing About Acute Respiratory Distress Syndrome and COVID-19 Set for Monday with ARDS Foundation and Dr. Michael Matthay, issued 13-Mar-2020 by ARDS Foundation over PR Newswire, we are advised by the company that the webinar information in paragraph 1 has been updated. Attendees can register for the webinar by visiting:

CAMBRIDGE, Mass., March 16, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2019.Leap Highlights:Entered into an exclus

CAMBRIDGE, Mass., March 16, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced updated results from the Phase 2 PIONEER trial of avapritinib in patients with indolent systemic mastocytosis (SM) showing significant clinical imp